secwatch.observer — SEC 8-K summary
======================================

Issuer:     IDEXX LABORATORIES INC /DE (IDXX)
CIK:        0000874716
Form:       8-K
Filed at:   2022-02-02T23:59:59+00:00
Accession:  0001564590-22-003449
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IDEXX Q4 revenue $801M (+11%), full-year EPS $8.60 (+28%); guides 2022 revenue $3.5-$3.565B
--------------------------------------------------------------------------------

- Q4 revenue $801M, up 11% reported and 10.5% organic; CAG Diagnostics recurring revenue grew 13%.
- Full-year EPS $8.60, up 28% reported and 29% comparable; operating margin expanded 330 bps reported.
- Record premium instrument placements drove 14% YoY expansion of global installed base.
- Initial 2022 guidance: revenue $3,500M-$3,565M (9-11% growth), EPS $9.27-$9.59 (8-11% growth).
- U.S. same-store clinical visit growth 2% in Q4; on a two-year basis, visits up 5.5%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/874716/000156459022003449/0001564590-22-003449-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/874716/000156459022003449/idxx-8k_20220202.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-003449

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer